For more than 60 years, EMD Serono, a business of Merck KGaA, Darmstadt, Germany, has been a pioneer in the field of fertility treatment, innovating to meet customers’ needs within the Assisted Reproductive Technologies (ART) process.
With the creation of our Fertility Technologies division, EMD Serono is using knowledge gained from working with the infertility community over many decades to address current challenges in the IVF Lab. The goal of our division is to bring a portfolio of innovative automated solutions to improve standardization and consistency to IVF labs, ultimately aiming for better outcomes for patients facing infertility.
Our launch of a dedicated Fertility Technologies business in the United States, builds on the global partnership that Merck KGaA, Darmstadt, Germany formed with Genea Biomedx in May 2015. The partnership provided Merck KGaA, Darmstadt, Germany, with the global marketing and commercialization rights to the company’s product portfolio.
We are continuously evaluating and investing in projects that explore the use of innovative technology to freeze and identify the embryos with highest implantation potential; improve culture conditions; and virtrification, which aim to help clinics deliver the best outcomes for their patients. The diagram above highlights the areas in the lab that EMD Serono intends to focus on in the future.
EMD Serono is committed to advancing fertility treatment beyond drugs and to further innovation in technologies by expanding our technologies portfolio in the coming years.